MULTIMERIC FORMS OF MEMBERS OF THE STEROID/THYROID SUPERFAMILY OF RECEPTORS WITH THE ULTRASPIRACILE RECEPTOR

Inventors: Ronald M. Evans, La Jolla; Michael B. McKeown; Anthony E. Oro, both of San Diego, all of CA (US); William A. Segraves, Ambler, PA (US); Tso-Pang Yao, La Jolla, CA (US)

Assignee: The Salk Institute Biological Studies, San Diego, CA (US)

Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

Appl. No.: 08/486,403
Filed: Jun. 5, 1995

Related U.S. Application Data

Continuation of application No. 07/897,935, filed on Jul. 2, 1992, now abandoned, which is a continuation of application No. 07/497,935, filed on Mar. 22, 1990, now abandoned.

References Cited

U.S. PATENT DOCUMENTS
5,401,830 * 3/1995 McKenzie ....................................... 530/371

FOREIGN PATENT DOCUMENTS
0 244 221 4/1987 (EP).

OTHER PUBLICATIONS

Murray and Towle, “Identification of Nuclear Factors that Enhance Binding of the Thyroid Hormone Receptor to a Thyroid Hormone Response Element”, Molecular Endocrinology vol. 3:1434–1442 (1989).

Primary Examiner—Bradley L. Sisson
(74) Attorney, Agent, or Firm—Gray Cary Ware & Freidinrich LLP; Stephen E. Reiter

ABSTRACT

In accordance with the present invention, it has been discovered that various members of the steroid/thyroid superfamily of receptors can interact with the investigational ultraspriacle receptor, to form multimeric species. Accordingly, the interaction of at least one member of the steroid/thyroid superfamily of receptors with at least the dimerization domain of the ultraspriacle receptor modulates the ability of said member of the steroid/thyroid superfamily of receptors to transactivate transcription of genes maintained under hormone expression control in the presence of the cognate ligand for said member of the superfamily.

17 Claims, 2 Drawing Sheets
OTHER PUBLICATIONS


* cited by examiner
U.S. Patent

FIGURE 1

USP

hRXR α

hRAR α

hGR

DNA

LIGAND

1 104 169 224

1 135 200 225

1 88 153 198

1 421 486 528

514

462

462

777

19%

86%

44%

15%

59%

24%

24%

53%

20%
MULTIMERIC FORMS OF MEMBERS OF THE STERIOD/THYROID SUPERFAMILY OF RECEPTORS WITH THE ULTRASPIRACLE RECEPTOR

This application is a continuation of U.S. application Ser. No. 07/907,908, filed Jul. 2, 1992, now abandoned, which is a continuation of application U.S. patent application Ser. No. 07/497,935 filed Mar. 22, 1990, now abandoned, the entire contents of which are hereby incorporated by reference herein.

This invention was made with Government support under Grant No. GM 36549, awarded by the National Institutes of Health. The Government has certain rights in the invention.

FIELD OF THE INVENTION

The present invention relates to interactions between members of the steroid/thyroid superfamily of receptor proteins, novel combinations of various members of the steroid/thyroid superfamily of receptor proteins, and methods of using such combinations.

BACKGROUND OF THE INVENTION

Transcriptional regulation of development and homeostasis in complex eukaryotes, including humans and other mammals, birds, fish, insects, and the like, is controlled by a wide variety of regulatory substances, including steroid and thyroid hormones. These hormones exert potent effects on development and differentiation of phylogenetically diverse organisms. The effects of hormones are mediated by interaction with specific, high affinity binding proteins referred to as receptors.

A number of receptor proteins are known, each specific for steroid hormones (e.g., estrogens (estrogen receptor), progesterones (progesterone receptor), glucocorticoid (glucocorticoid receptor), androgens (androgen receptor), aldosterone (mineralocorticoid receptor), vitamin D (vitamin D receptor), retinoids (e.g., retinoic acid receptor) or thyroid hormones (e.g., thyroid hormone receptor). Receptor proteins have been found to be distributed throughout the cell population of complex eukaryotes in a tissue specific fashion.

Molecular cloning studies have made it possible to demonstrate that receptors for steroid, retinoid and thyroid hormones are all structurally related and comprise a superfamily of regulatory proteins. These regulatory proteins are capable of modulating specific gene expression in response to hormone stimulation by binding directly to cis-acting elements.

It is known that steroid or thyroid hormones, protected forms thereof, or metabolites thereof, enter cells and bind to the corresponding specific receptor protein, initiating an allosteric alteration of the protein. As a result of this alteration, the complex of receptor and hormone (or metabolite thereof) is capable of binding with high affinity to certain specific sites on chromatin. One of the primary effects of steroid and thyroid hormones is an increase in transcription of a subset of genes in specific cell types.

A number of transcriptional control units which are responsive to members of the steroid/thyroid superfamily of receptors have been identified. These include the mouse mammary tumor virus 5'-long terminal repeat (MTV LTR), responsive to glucocorticoid, aldosterone and androgen hormones; the transcriptional control units for mammalian growth hormone genes, responsive to glucocorticoids, estrogens and thyroid hormones; the transcriptional control units for mammalian prolactin genes and progesterone receptor genes, responsive to estrogens; the transcriptional control units for avian ovulbin genes, responsive to progesterones; mammalian metallothionein gene transcriptional control units, responsive to glucocorticoids; and mammalian hepatic α2- globulin gene transcriptional control units, responsive to androgens, estrogens, thyroid hormones, and glucocorticoids.

A major obstacle to further understanding and more widespread use of the various members of the steroid/thyroid superfamily of hormone receptors has been a lack of awareness of the possible interactions of various members of the steroid/thyroid superfamily of hormone receptors, and an understanding of the implications of such interactions on the ability of members of the steroid/thyroid superfamily of hormone receptors to exert transcriptional regulation of various physiological processes.

DNA binding studies on the glucocorticoid receptor (GR) and the estrogen receptor (ER) have indicated that these receptors bind to their hormone response elements (HREs) as homodimeric complexes [see, for example, Kumar and Chambon in Cell 55:145–156 (1988) and Tsi et al., in Cell 55:361–369 (1988)]. However, recent biochemical analysis has revealed that some other receptors (including retinoic acid receptor (RAR), thyroid hormone receptor (TR), and the vitamin D receptor (VDR) can not efficiently bind to cognate response elements as homodimers, but rather require additional factors present in cell nuclear extracts to achieve high affinity DNA binding [see, for example, Murray and Towle in Molecular Endocrinology 3:1434–1442 (1989), Glass et al., in Cell 63:729–738 (1990), Liao et al., in Proc. Natl. Acad. Sci. USA 87:9751–9755 (1990), and Yang et al., in Proc. Natl. Acad. Sci. USA 88:3559–3563 (1991)].

Several recent reports have identified members of the retinoid X receptor family (RXR, see, for example, Mangelsdorf et al., in Nature 345:224–229 (1990) and Genes & Development 6:329–344 (1992), and Leid et al., in Cell 68:377–395 (1992)) as factors that can interact with RAR and potentiate DNA binding by forming a novel RAR/RXR heterodimer [see, for example, Yu et al., in Cell 67:1251–1266 (1991), Kliwer et al., in Nature 355:446–449 (1992), Leid et al., supra, and Zhang et al., in Nature 355:441–446 (1992)]. Interestingly, RXR is not the only receptor with which RAR can interact. In fact, RXR has been found to be capable of heterodimerizing with several other members of the nuclear receptor superfamily, including VDR, TR (see Kliwer, et al, supra) and peroxisome proliferator-activated receptor (PPAR; see, for example, Issemann and Green in Nature 347: 645–650 (1990)).

Although the physiological significance of these interactions remains to be definitively determined, the capability of nuclear receptors to heterodimerize suggests the existence of an elaborate network through which distinct hormone receptor classes are capable of modulating each other’s activity. In addition, the possible existence of other factors that can potentially interact with members of the steroid/thyroid superfamily and potentiate DNA binding by forming novel heteromeric species remains to be determined.

BRIEF DESCRIPTION OF THE INVENTION

In accordance with the present invention, we have discovered that various members of the steroid/thyroid superfamily of receptors can combine with the insect derived...
ultraspirecle receptor (or functional fragments thereof comprising at least the dimerization domain thereof) to form a multimeric complex receptor.

Accordingly, the combination of a first receptor species with the ultraspirecle receptor (or a truncated form thereof comprising at least the dimerization domain thereof) is capable of modulating the ability of the first receptor species to trans-activate transcription of genes maintained under steroid hormone or hormone-like expression control in the presence of cognate ligand for said first receptor.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 presents a comparison of amino acid identity for various domains of invention ultraspirecle receptor (uSp) in comparison with previously identified receptors human RXR-alpha (hRXRa), human retinoic acid receptor-alpha (hRARa) and human glucocorticoid receptor (hGR).

FIG. 2(A) presents the % conversion of substrate by chloramphenicol acetyltransferase (CAT) as a result of cotransfection of mammalian (CV1) cells with edysgone receptor (EeR) encoding vector and/or ultraspirecle receptor (uSp) encoding vector along with CAT reporter vector which contains an edysgone response element (EeRe).

FIG. 2(B) presents the % conversion of substrate by chloramphenicol acetyltransferase (CAT) as a result of cotransfection of mammalian (CV1) cells with GeRe (the N-terminal domain of the glucocorticoid receptor fused to the edysgone receptor DNA binding domain and ligand binding domain) encoding vector, and/or ultraspirecle receptor (uSp) encoding vector along with CAT reporter vector which contains an edysgone response element.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there are provided multimeric receptor species which belong to the steroid/thyroid superfamily of receptors, comprising at least one member of the steroid/thyroid superfamily of receptors, and the ultraspirecle receptor.

As employed herein, the term “dimerization domain(s)” of a member of the steroid/thyroid superfamily of receptors refers to that portion (or portions) of the receptor which is involved in the formation of a given multimeric complex receptor. Dimerization domain(s) typically comprise at least a portion of the carboxy-terminal portion of the receptor (i.e., the carboxy-terminal portion of a receptor with respect to the DNA-binding domain thereof) and/or at least a portion of the DNA binding domain itself. Multiple domains of a given receptor can act in concert as well as independently.

Combinations contemplated by the present invention can broadly refer to as “multimeric species”, which is intended to embrace all of the various oligomeric forms in which members of the steroid/thyroid superfamily of receptors (including fragments thereof comprising the dimerization domains thereof) are capable of associating with at least the dimerization domain of the ultraspirecle receptor. Thus, reference to “combinations” of steroid receptors or “multimeric” forms of steroid receptors with at least the dimerization domain of the ultraspirecle receptor includes heterodimeric combinations of one member of the steroid/thyroid superfamily of receptors (including fragments thereof comprising the dimerization domain thereof) with at least the dimerization domain of the ultraspirecle receptor, heterotrimetric combinations of one or two members of the steroid/thyroid superfamily of receptors (including fragments thereof comprising the dimerization domains thereof) with at least the dimerization domain of the ultraspirecle receptor, heterotrimetric combinations of one or two members of the steroid/thyroid superfamily of receptors (including fragments thereof comprising the dimerization domains thereof) with at least the dimerization domain of the ultraspirecle receptor, and the like.

As employed herein, the term “ultraspirecle receptor” refers to a novel invertebrate polypeptide which has a DNA binding domain of about 66 amino acids with at least 9 Cys residues, more than about 75% amino acid identity in comparison with the DNA binding domain of hRXR-alpha (see Mangelsdorf et al., 1990, supra), less than about 60% amino acid identity in comparison with the DNA binding domain of hGR, and less than about 60% amino acid identity in comparison with the DNA binding domain of hRARa. Invention polypeptide can be further characterized by having less than 50% (but typically greater than 40%) amino acid identity in comparison with the ligand binding domain of hRXR-alpha, but less than 25% amino acid identity in comparison with the ligand binding domains of either hGR or hRARa. A sequence comparison of amino acid identity between invention receptor and several other receptors is presented in FIG. 1.

The deduced amino acid sequence for the ultraspirecle receptor is presented in SEQ ID NO:2 [see also, Oro et al., in Nature 347: 298–301 (1990)]. Also contemplated within the scope of the present invention are peptides comprising a DNA binding domain with substantially the same sequence as that of amino acids 104–169 shown in SEQ ID NO:2 (i.e., the DNA binding domain of the ultraspirecle receptor). As employed herein, the term “substantially the same amino acid sequence” refers to amino acid sequences having at least about 80% identity with respect to the reference amino acid sequence, and retaining comparable functional and biological properties characteristic of the protein encoded by the reference amino acid sequence. Preferably, proteins having “substantially the same amino acid sequence” will have at least about 90% amino acid identity with respect to the reference amino acid sequence; with greater than about 95% amino acid sequence identity being especially preferred. Also contemplated within the scope of the present invention are polypeptides having substantially the same sequence as that of amino acids 1–513 shown in SEQ ID NO:2. A presently preferred polypeptide of the invention is the polypeptide encoded by vector pXR2CS [see Oro et al., supra].

As employed herein, the phrase “members of the steroid/thyroid superfamily of receptors” refers to all of the various isoforms of hormone binding proteins that operate as ligand-dependent transcription factors, including members of the steroid/thyroid superfamily of receptors for which specific ligands have not yet been identified (referred to hereinafter as “orphan receptors”). Each such protein has the intrinsic ability to bind to a specific DNA sequence (i.e., regulatory sequence) associated with the target gene. The transcriptional activity of the gene is modulated by the presence or absence of the cognate hormone (ligand) as a result of binding of ligand to receptor, enabling interaction of receptor with the regulatory sequence.

The DNA-binding domains of all members of this superfamily of receptors are related, consisting of 66–68 amino acid residues, and possessing about 20 invariant amino acid residues, including nine cysteines. A member of the superfamily can be characterized as a protein which contains these diagnostic amino acid residues, which are part of the DNA-binding domain of such known steroid receptors as
human glucocorticoid receptor (amino acids 421–486), the estrogen receptor (amino acids 185–250), the mineralocorticoid receptor (amino acids 603–668), the human retinoic acid receptor (amino acids 88–153), and the like. The highly conserved amino acids of the DNA-binding domain of members of the superfamily are as follows:

\[
\text{Cys-XX-Cys-XX-Asp^* - X-Ala^* - X-Gly^* - X-Tyr^* - X-XX-XX-Cys-XX-
\text{Cys-XX-Asp^* - X-Phe-Phe-X-Arg-XX-XX-XX-XX-XX-XX-XX-XX-XX-XX-XX-XX-XX-XX-
\text{Cys-XX-Arg^* - X-XX-XX-Cys-XX-XX-Gly^* - Met (SEQ ID No: 3)}
\]

wherein X designates non-conserved amino acids within the DNA-binding domain; the amino acid residues denoted with an asterisk are residues that are almost universally conserved, but for which variations have been found in some identified hormone receptors; and the residues enclosed in parenthesis are optional residues (thus, the DNA-binding domain is a minimum of 66 amino acids in length, but can contain several additional residues).

Exemplary members of the steroid/thyroid superfamily of receptors (including the various isoforms thereof) include steroid receptors such as glucocorticoid receptor, mineralocorticoid receptor, progesterone receptor, androgen receptor, vitamin D receptor, and the like; plus retinoid receptors, such as the various isoforms ofRAR (e.g., RARα, RARβ, or RARγ), the various isoforms of RXR (e.g., RXRα, RXRβ, or RXRγ), and the like; thyroid receptors, such as TRα, TRβ, and the like; insect derived receptors such as the edysone receptor, and the like; as well as other gene products which, by their structure and properties, are considered to be members of the superfamily, as defined hereinabove, including the various isoforms thereof (even though ligands thereof have not yet been identified; such receptors are referred to as “orphan receptors”). Examples of orphan receptors include HNF4 [see, for example, Sladek et al., in *Genes & Development* 4: 2353–2365 (1990)], the COUP family of receptors [see, for 25 example, Miyajima et al., in *Nucleic Acids Research* 16: 11075–11074 (1988)], and Wang et al., in *Nature* 340: 163–166 (1989)], COUP-like receptors and COUP homologs, such as those described by Mlodzik et al., in *Cell* 60: 211–224 (1990) and Ladisl et al., in *Science* 251: 561–565 (1991), various isoforms of peroxisome proliferator-activated receptors (PPARs; see, for example, Gropman and Green, supra), the insect derived knirps and knirps-related receptors, and the like.

The formation of multimeric receptor(s) can modulate the ability of member(s) of the steroid/thyroid superfamily of receptors to trans-activate transcription of genes maintained under expression control in the presence of ligand for said receptor. The actual effect on activation of transcription (i.e., enhancement or repression of transcription activity) will vary depending on the receptor species which are part of the multimeric receptor, as well as on the response element with which the multimeric species interacts. Thus, for example, a heterodimer of the edysone receptor with the ultraspireal receptor promotes the ability of the edysone receptor to induce trans-activation activity in the presence of an edysone response element (see, for example, SEQ ID NO:26).

In accordance with another embodiment of the present invention, there is provided a method to modulate, in an expression system, the transcription activation of a gene by a member of the steroid/thyroid superfamily of receptors in the presence of ligand therefor, wherein the expression of said gene is maintained under the control of a hormone response element, said method comprising:

- exposing said system to at least the dimerization domain of the ultraspireal receptor, in an amount effective to form a multimeric complex receptor with said member of the steroid/thyroid superfamily of receptors.

Exposure of said system to at least the dimerization domain of the ultraspireal receptor is accomplished by directly administering ultraspireal receptor (or fragments thereof that allow modification of the receptor through the formation of heterodimeric receptor species) to said system, or by exposing said system to compound(s) and/or condition(s) which induce expression of the ultraspireal receptor (or dimerization domain thereof). The resulting multimeric receptor species is effective to modulate transcription activation of said gene.

As employed herein, the term “modulate” refers to the ability of a given multimeric complex receptor to either enhance or repress the induction of transcription of a target gene by a given receptor, relative to such ability of said receptor in its uncomplexed state. The actual effect of multimerization on the transcription activity of a receptor will vary depending on the specific receptor species which are part of the multimeric complex receptor, and on the response element with which the multimeric complex receptor interacts. Thus, for example, formation of a heterodimer of the edysone receptor and the ultraspireal receptor provides enhanced trans-activation activity with respect to the ability of the edysone receptor alone to promote trans-activation. Conversely, formation of a heterodimer of the edysone receptor and the dimerization domain of the ultraspireal receptor should prevent the ability of edysone to promote trans-activation activity, since the resulting multimeric complex receptor will have a reduced ability to bind DNA, relative to the ability of edysone-asp multimeric complex to bind DNA.

The term “edysone” is employed herein in its generic sense (in accordance with common usage in the art), referring to compounds with the appropriate biological activity, in analogy with the terms estrogen or progesterin [see, for example, Cherbas et al., in *Biochemistry, Metabolism and Mode of Action of Invertebrate Hormones* (ed. J. Hoffmann and M. Porchet), p. 305–322; Springer-Verlag, Berlin]. 20-Hydroxyecdysone is the major naturally occurring edysone. Analogos of the naturally occurring edycsones are also contemplated within the scope of the present invention, such as for example, ponasterone A, 26-sodoponasterone A, muristerone, inokosterone, 20-mesylinokosterone, and the like.

As employed herein, the phrase “hormone response element” refers to short cis-acting sequences (i.e., having about 20 bp) that are required for hormonal (or ligand) activation of transcription. The attachment of these elements to an otherwise hormone-nonresponsive gene causes that gene to become hormone responsive. These sequences, commonly referred to as hormone response elements (HREs), function in a position- and orientation-independent fashion. Unlike other enhancers, the activity of HREs can be modulated by the presence or absence of ligand. See, for example, Evans, *Science* 240: 889–895 (1988), and the references cited therein. In the present specification and claims, the term “hormone response element” is used in a generic sense to mean and embody the functional characteristics implied by all terms used in the art to describe these sequences.

Hormone response elements contemplated for use in the practice of the present invention include naturally occurring response elements as well as modified forms thereof (see, for example, SEQ ID NOS:7, 12, 15, 25, 26, 28 and 29), as well as synthetic response elements which can be composed of two or more “half sites”, wherein each half site comprises the sequence.
wherein

R is selected from A or G;
B is selected from G, C, or T;

each N is independently selected from A, T, C, or G; and

M is selected from A or C;

and with the proviso that at least 4 nucleotides of said -RGBNNM- sequence are identical with the nucleotides at corresponding positions of the sequence -AGGTCA-, or the half-sites of ecdysone response elements (EcREs) (see, for example, SEQ ID NOs:26, 28 and 29) and

wherein the nucleotide spacing between each of said half-sites falls in the range of 0 up to 15 nucleotides, N.

When one of the half sites described above is incorporated into a synthetic response element in a direct repeat motif, and such half site varies by 2 nucleotides from the preferred sequence of -AGGTCA-, it is preferred that the other half site of the response element be the same as, or vary from the preferred sequence by no more than 1 nucleotide. It is presently preferred that the 3'-half site (or downstream half site) of a pair of half sites vary from the preferred sequence by at most 1 nucleotide.

When the above-described half sites are combined in direct repeat fashion (rather than as palindromic constructs), the resulting synthetic response elements are referred to as “DR-x”, wherein “DR” refers to the direct repeat nature of the association between the half sites, and “x” indicates the number of spacer nucleotides between each half site.

Exemplary response elements useful in the practice of the present invention are derived from variations of half sites having sequences selected from, for example, -AGGTCA-, -GGTTCA-, -GGGTGA-, -AGGTGA-, -GGTTCA-, and the like.

The nucleotides employed in a non-zero spacer are independently selected from C, T, G or A.

Exemplary three nucleotide spacers include -AGG-, -ATG-, -ACG-, -CGA-, and the like. Exemplary four nucleotide spacers include -CAGG-, -GCGG-, -TTCG-, and the like. Exemplary five nucleotide spacers include -CCAGG-, -ACAGG-, -CCGAA-, -CTGAC-, -TTGAC-, and the like.

Exemplary response elements contemplated by the present invention include the following DR-3 elements:

5'-AGGTCA-AGG-AGGTCA-3' (SEQ ID No. 4),
5'-GGTTGA-AGG-AGGTCA-3' (SEQ ID No. 5),
5'-GGGTGA-ACG-GGGCA-3' (SEQ ID No. 7),
5'-GGTTCA-CGA-GGTICA-3' (SEQ ID No. 9),

the following DR-4 elements:

5'-AGGTCA-CAGG-AGGTCA-3' (SEQ ID No. 8),
5'-AGGTCA-CAGG-AGGTCA-3' (SEQ ID No. 9),
5'-AGGTCA-CAGG-AGGTCA-3' (SEQ ID No. 10),
5'-GGGTGA-GGAG-AGGACA-3' (SEQ ID No. 11),
5'-GGGTCA-TTTCAGG-AGGTCA-3' (SEQ ID No. 12),

the following DR-5 elements:

5'-AGGTCA-CAGG-AG GTACA-3' (SEQ ID No. 13),
5'-AGGTCA-CAGG-AGGTCA-3' (SEQ ID No. 14),
5'-GGTTCA-CGGGA-AGGTCA-3' (SEQ ID No. 15),
(iii) the ultraspiracle receptor;

said method comprising administering to said subject an effective amount of said associated ligand; wherein said ligand is not normally present in the cells of said subject; and wherein said ligand is not toxic to said subject.

As employed herein, the term “exogenous” (or “foreign”) genes refers to both wild type genes and therapeutic genes, which are introduced into the subject in the form of DNA or RNA, either natural or synthetic. The gene of interest can be introduced into target cells (for in vitro applications), or the gene of interest can be introduced directly into a subject, or indirectly introduced by the transfer of transformed cells into a subject.

“Wild type” genes are those that are native to cells of a particular type, but which may be undesirably overexpressed in these cells, or may not be expressed in these cells in biologically significant levels. Thus, for example, while a synthetic or natural gene coding for human insulin would be exogenous genetic material to a yeast cell (since yeast cells do not naturally contain insulin genes), a human insulin gene inserted into a human skin fibroblast cell would be a wild type gene with respect to that cell since human skin fibroblasts contain the genetic material encoding human insulin, although human skin fibroblasts do not express human insulin in biologically significant levels.

Wild type genes contemplated for use in the practice of the present invention include genes which encode a gene product:

the substantial absence of which leads to the occurrence of a non-normal state in said subject; or

a substantial excess of which leads to the occurrence of a non-normal state in said subject; and

the like.

As employed herein, the phrase “therapeutic gene” refers to genes which impart a beneficial function to the host cell in which such gene is expressed. Therapeutic genes are those that are not naturally found in host cells. For example, a synthetic or natural gene coding for authentic human insulin would be therapeutic when inserted into a skin fibroblast cell so as to be expressed in a host human, where the host human is not otherwise capable of expressing functionally active human insulin in biologically significant levels.

Therapeutic genes contemplated for use in the practice of the present invention include genes which encode a gene product:

which is toxic to the cells in which it is expressed; or

which imparts a beneficial property to said subject (e.g., disease resistance, etc);

and the like.

Exogenous genetic material or genes useful in this embodiment of the present invention include genes that encode secretory proteins that can be released from said cell; enzymes that can metabolize a substrate from a toxic form to a benign form, or from a benign form to a useful form; regulatory proteins; cell surface receptors; and the like. Such useful genes include, but are not limited to, genes that encode blood clotting factors such as human factors VIII and IX; genes that encode hormones such as insulin, parathyroid hormone, luteinizing hormone releasing factor (LHRR), alpha and beta seminal inhibins, and human growth hormone; genes that encode proteins such as enzymes, the absence of which leads to the occurrence of an abnormal state in said subject; genes encoding cytokines or lymphokines such as interferons, granulocyte macrophage colony stimulating factor (GM-CSF), colony stimulating factor-1 (CSF-1), tumor necrosis factor (TNF), and erythropoietin (EPO); genes encoding inhibitor substances such as alpha,-antitrypsin; genes encoding substances that function as drugs, e.g., genes encoding the diphtheria and cholera toxins; and the like.

Hormone response elements contemplated for use in this embodiment of the present invention involving modulating the expression of an exogenous gene in a subject include any sequence responsive to the above-described multimeric complex receptors, such as insect response elements, and the like. See, for example, SEQ ID Nos: 26, 28 and 29.

Insect response elements contemplated for use in modulating the expression of an exogenous gene in a subject according to the present invention include, for example, ecdysone response elements, and the like.

Such response elements are operably linked to a suitable promoter for expression of the target gene product. As used herein, the term “promoter” refers to a specific nucleotide sequence recognized by RNA polymerase, the enzyme that initiates RNA synthesis. This sequence is the site at which transcription can be specifically initiated under proper conditions. When exogenous genes, operatively linked to a suitable promoter, are introduced into the cells of a suitable host, the exogenous genes are subject to expression control in the presence of hormone or hormone-like compounds not normally present in the host cells. Exemplary promoters include AMTV, ASV, CDC1, and the like.

As employed herein, the phrase “receptor which is not normally present in the cells of said subject” refers to receptors which are not endogenous to the host in which the invention process is being carried out. Receptors which are not endogenous to the host include endogenous receptors modified so as to be non-responsive to ligands which are endogenous to the host in which the invention process is being carried out.

Receptor(s) not normally present in the cells of the subject and ultraspiracle receptor (or fragments thereof) can be provided to said subject by direct introduction of the proteins themselves, by introduction of RNA or DNA construct(s) encoding said receptors, by introduction of cells harboring genes encoding said receptor and/or response element, and the like. This can be accomplished in a variety of ways, e.g., by microinjection, retroviral infection, electroporation, lipofection, and the like.

As employed herein, the phrase “associated ligand” refers to a substrate or compound which, inside a cell, binds to the receptor protein, thereby creating a ligand/receptor complex, which in turn can bind to an appropriate hormone response element. An associated ligand therefore is a compound which acts to modulate gene transcription for a gene maintained under the control of a hormone response element, and includes compounds such as hormones, growth substances, non-hormone substances that regulate growth, and the like. Ligands include steroid or steroid-like hormones, retinoids, thyroid hormones, pharmacologically active compounds, and the like. Individual ligands may have the ability to bind to multiple receptors.

In accordance with a still further embodiment of the present invention, there is provided a method of inducing the expression of an exogenous gene in a subject containing:

(i) a DNA construct encoding an exogenous gene product under the control of a hormone response element; wherein said response element is not normally present in the cells of said subject,

(ii) DNA encoding a receptor which is not normally present in the cells of said subject under the control of an inducible promoter; wherein said receptor, in the presence of its associated ligand and the ultraspiracle receptor, binds to said hormone response element,
(iii) the ultrastrapilce receptor, and (iv) the associated ligand for said receptor;

said method comprising subjecting a subject to conditions suitable to induce expression of said receptor.

In accordance with yet another embodiment of the present invention, there is provided a method of inducing expression of an exogenous gene product in a subject containing a DNA construct encoding said product under the control of a hormone response element; wherein said response element is not normally present in the cells of said subject, said method comprising introducing into said subject:

a receptor which is not normally present in the cells of said subject, wherein said receptor, in combination with its associated ligand and the ultrastrapilce receptor, binds to a hormone response element, activating transcription therefrom,

the ultrastrapilce receptor, and

the associated ligand for said receptor which is not normally present in the cells of said subject.

In accordance with this embodiment of the present invention, receptor can be provided directly to said subject as the protein, or indirectly by administering to said subject a second DNA construct encoding said receptor, or by administering to said subject cells harboring such constructs. When introduced as part of a second DNA construct, expression of said exogenous gene product and the receptor is preferably maintained under the control of a tissue specific promoter.

In accordance with a further embodiment of the present invention, there is provided a method for the expression of recombinant products detrimental to a host organism, said method comprising:

transforming suitable host cells with:

(i) a construct comprising a sequence encoding said recombinant product under the control of a hormone response element;

wherein said response element is not normally present in the cells of said host, and

(ii) DNA encoding a receptor not normally present in said host cells;

growing said host cells to the desired level in the substantial absence of hormone(s) which, in combination with said receptor not normally present in the cells of said host and ultrastrapilce receptor, is capable of binding said hormone response element, and

inducing expression of said recombinant product by introducing into said host cells the ultrastrapilce receptor and hormone(s) which, in combination with said receptor not normally present in the cells of said host, bind to said response element.

In one aspect of this embodiment of the invention, wherein host is employed as an expression system for the production of a recombinant product which is toxic to the host, recombinant product is induced only after cell growth (as opposed to protein expression conditions) has produced a desired density of cell mass. Thus, the desired level of growth in accordance with this embodiment is a level which produces a high cell density, and thereafter expression of product is induced. Conditions suitable for cell growth (and for protein expression, when desired) can be readily determined by those of skill in the art.

In another aspect of this embodiment of the present invention, wherein the host harbors a DNA construct as described above, expression of the construct to produce the detrimental product causes ablation of the cells harboring said construct. In this aspect, the desired level of growth is that level appropriate to ensure the desired distribution of cells harboring the inducible construct. Thus, expression will be induced when it is desired to ablate such cells.

As used herein, “ablation” refers to removing or eliminating specific cell types in a culture of a cell population, or in a transgenic animal host by means of a DNA construct that encodes a protein whose presence is not per se toxic to the cells, but which can confer upon the cells a toxic potential due to the ability of the protein to control the expression of substances that are or will become toxic to the cells.

The elimination of specific cell-type(s) or specific cell line(s) in accordance with one aspect of the present invention produces a cell population which is substantially free of cells which are not normally present in the wild-type cell population. The elimination of specific cell-type(s) or specific cell line(s), in accordance with another aspect of the present invention, produces a defined altered state in the treated subject.

Cell(s) or cell line(s) contemplated to be eliminated in accordance with the present invention can be a cell or cell line capable of providing a desirable component to a cell population, as an exogenous gene product; wherein the ability to eliminate said cell or cell line from said cell population is desired, e.g., once said population achieves the ability to produce sufficient quantities of such component as an endogenous gene product; or, the cell line to be eliminated can be a diseased cell line or a cell line predisposed to a disease state.

Normal cell(s) or cell line(s) contemplated to be eliminated in accordance with the present invention are cell(s) or cell line(s), the elimination of which would result in the creation of a defined altered state in the cell population.

In accordance with a still further embodiment of the present invention, there is provided a method to distinguish the physiological effect of a first hormone receptor in a host from other hormone receptors in said host which respond to the same ligand, said method comprising:

replacing the ligand binding domain of said first receptor with a ligand binding domain from an exogenous receptor to produce a chimeric receptor maintained under the control of a tissue specific promoter;

wherein said exogenous receptor and the ligand to which the exogenous receptor responds are not normally present in said host; and

wherein said exogenous receptor, in the presence of its associated ligand, binds to a hormone response element, thereby activating said response element, and thereafter

monitoring the production of product(s) whose expression is controlled by said first hormone receptor when said host is exposed to ultrastrapilce receptor and ligand to which said exogenous receptor responds.

In accordance with yet another embodiment of the present invention, there is provided a method to render a mammalian hormone receptor uniquely responsive to a ligand not endogenous to host(s) in which said receptor is normally found, said method comprising:

replacing the ligand binding domain of said receptor with a ligand binding domain from a second receptor;

wherein said second receptor is not normally present in said host; and wherein the ligand to which the second receptor responds is not normally present in said host.

In accordance with a still further embodiment of the present invention, there is provided a method to determine the ligand(s) to which orphan receptor(s) responds, said method comprising:
monitoring a host cell containing a reporter construct and a hybrid receptor for expression of product(s) of said reporter construct upon contacting said host cell with potential ligands for said orphan receptor and the ultraspiracle receptor;

wherein said reporter construct comprises a gene encoding a reporter molecule, operatively linked for transcription to a steroid or steroid-like hormone response element; wherein said response element is not normally present in the cells of said host;

wherein said hybrid receptor comprises:

the N-terminal domain and DNA binding domain of a member of the steroid/thyroid superfamily of receptors, wherein said member is not normally present in the host cells, and wherein said member, in the presence of its associated ligand, binds said response element, activating transcription therefrom, and

the ligand binding domain of said orphan receptor.

In accordance with yet another embodiment of the present invention, there is provided an isolated DNA which encodes the ultraspiracle receptor, as described above as well as functional fragments thereof. The complete nucleotide sequence for the ultraspiracle receptor is presented in SEQ ID NO:1 [see also, Oro et al., in Nature 347: 298–301 (1990)]. Also contemplated within the scope of the present invention are sequences encoding polypeptides comprising a DNA binding domain with substantially the same sequence as that of amino acids 104–169 shown in SEQ ID NO:2 (i.e., the DNA binding domain of the ultraspiracle receptor). Also contemplated are sequences encoding polypeptides having substantially the same sequence as that of amino acids 1–513 shown in SEQ ID NO:2. Also contemplated are sequences having substantially the same nucleotide sequence as nucleotides 163–1704 shown in SEQ ID NO:1.

As employed herein, the term “substantially the same” refers to DNA having at least about 70% homology with respect to the nucleotide sequence of the DNA fragment with which subject DNA is being compared. Preferably, DNA “substantially the same as” a comparative DNA will be at least about 80% homologous to the comparative nucleotide sequence; with greater than about 90% homology being especially preferred. Also contemplated are DNAs able to hybridize to the above-described sequences, and having substantially the same functional properties thereof. A presently preferred DNA of the invention is the EcoRI fragment of vector pX2CS [see Oro, et al., supra].

DNA of the invention can optionally be incorporated into expression vector(s) operative in a cell in culture to make the ultraspiracle receptor (or functional fragments thereof) by expression of said DNA in said cell. For example, the transcription of DNA can be controlled by the Drosophila melanogaster actin 5C promoter. Host cells which can be employed for expression of said DNA include Drosophila melanogaster Schneider line 2 cells, Kc cells, and the like.

The invention will now be described in greater detail by reference to the following non-limiting examples.

**EXAMPLES**

**Example 1**

**Plasmids**

CMX-EcR was constructed by digesting pAcEcR plasmid [Koelle et al., Cell Vol. 67:59–77 (1991)] with HindIII. The resulting HindIII fragment, which contains the EcR coding region, was then inserted into CMXPL1, a derivative of CMX expression vector [Umesono et al. Cell Vol. 65:1255–1266 (1991)]. Expression plasmid CMX-usp was made by inserting the EcoRI fragment from the cDNA clone [Oro et al., Nature Vol. 347:298–301 (1990)] which contains all the usp coding region into CMXPL1 vector. ΔMTV-EcRE5-CAT was constructed by ligation of an EcoRI-containing oligonucleotide (SEQ ID NO: 22):

```
5'-AGCTCAATGG ACAAGTGTCAG TGAACCCCTT GACCTCG-3'
```

into HindIII-cleaved ΔMTV-CAT [Hollenberg and Evans, Cell Vol. 55:899–906 (1988)]. Restriction analysis and sequencing of the construct indicated that it contains 5 copies of this oligonucleotide.

ΔEcR was constructed by ligation of a NotI/BamHI fragment containing the DNA and hormone binding domains of a modified EcR cDNA, EcRxn, in place of the DNA and hormone binding domains of the similarly modified glucocorticoid receptor expression construct pRSbGRnx [Giguere et al., Nature Vol. 330:624–629 (1987)]. The modified receptor cDNA was constructed using the site-directed mutagenesis procedure of Kunkel, T. A., Proceedings National Academy of Science USA Vol. 82:448–492 (1985) to insert NotI (employing SEQ ID NO:23 as the oligonucleotide template) and XhoI (employing SEQ ID NO:24 as the oligonucleotide template) sites immediately flanking the DNA binding domain. SEQ ID NO:23 is:

```
5'-CTGGGGCCAC GGCAGCCGTC GGACGCTGTT CGCT-3'
```

SEQ ID NO:24 is:

```
5'-GTGGGCAAT CGCTCGAGT GGCGCTCG-3'
```

This mutagenesis procedure results in conversion of amino acids 258–260 from ValGlnGlu to ArgProPro and amino acid 331 from Pro to Leu.

**Example II**

**Preparation of Receptor Protein, Cell Extracts and Gel Mobility Shift Assay**

To generate protein in vitro, suitable plasmids for human (h)RARα, hTRB, hVDR, rat PPAR, Drosophila (d)usp and dEcR were linearized with restriction enzyme 3′ of the termination codon. The linearized templates were used for in vitro transcription and then translation using rabbit reticulocyte lysate according to manufacturer’s instruction (Promega). Drosophila embryo extract was a gift from Dr. J. Kadonaga and prepared as described by Zoeller et al., in Genes & Development, Vol. 2:68–81 (1988). Schneider cell extracts were prepared following the procedures in Dunn et al., Nature Vol. 339:592–597 (1989) and Umesono et al. (1991), supra. The extraction buffer contained 0.4M KCl in 20 mM HEPES pH 7.5, 20% glycerol, 2 mM DTT and 1 mM PMSF.

For gel mobility shift assay, proteins were incubated with binding buffer, which contained 100 mM KCl, 7.5% glycerol, 20 mM HEPES pH 7.5, 2 mM DTT and 0.1% NP-40, on ice for 20 minutes in the presence of 2 μg of nonspecific competitor poly dl-dC and other oligo competitors. Then approximately 1 ng of 32P-DCTP probe, which was labelled to specific activity about 1–5x106 cpm/μg by fill-in reaction with Klenow fragments, was added to the reaction and incubated at room temperature for 20 minutes. Antiserum or preimmune serum was added 10 minutes after the probe was added. The reaction was then loaded into 5%
non-denaturing polyacrylamide gel in 0.5 X TBE running buffer [1 X TBE comprises 0.089M Tris borate, 0.089M boric acid and 0.002M EDTA]. After electrophoresis, the gel was dried for autoradiography.

Example III
Preparation of usp Antiserum

Primeres were designed to amplify the usp coding region which either covered the entire N-terminal and DNA binding domain (from amino acid 1 to 210; GST-uspN) or the complete coding region (GST-usp) by polymerase chain reaction (PCR). The amplified fragments were subcloned into PGEX2 vector (Pharmacia) for expression in bacteria. The expression of GST fusion protein was performed according to the manufacturer's directions (Pharmacia).

The fusion protein GST-uspN was prepared and fractionated on SDS polyacrylamide gel and the band corresponding to the fusion protein was excised. The gel slice was fragmented and used to immunize the rabbit at three week intervals. The rabbit sera were collected and tested by Western Blot for the ability to recognize usp protein. The positive sera were further purified by the procedure described in Vaughan et al., Methods in Enzymology. (Academic Press Vol. 168:588–617 (1989) with slight modification. Briefly, full length GST-usp fusion protein and GST protein were purified using Glutathione Sepharose 4B (Pharmacia). The purified proteins were individually coupled to Affigel 10 according to the manufacturer's protocol (BioRad).

To affinity purify the antibody, the crude antiserum was first incubated with GST-coupled Affigel for 2.5 hours at 4°C with gentle rocking. The unbound fraction was separated from the beads by centrifugation. The supernatant was then incubated with full length GST-usp coupled Affigel overnight at 4°C with gentle rocking. The contents were then packed into column and washed with 50 mM HEPES pH 7.5 supplemented with 0.5M NaCl. The bound antibodies were eluted by 100 mM glycine. The eluted fractions were neutralized with 1M Tris pH 8 and pooled, then dialyzed against PBS buffer which contains 0.02% of sodium azide. The purified antiserum was concentrated by Centrihot 30 (Amicon) before it was stored. This purified antibody is very specific as it does not cross react with RXRs. It also does not react with other closely related fly nuclear receptors including seven up (sup) type I, II [Modzik et al., Cell 60:211–224 (1990)].

Example IV
Cotransfection Assay

Transfection was performed with calcium-phosphate precipitation method as described previously [Umesono et al., Nature 336:262–264 (1989)]. CV1 monkey kidney cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% calf bovine serum. The cells were transfected for 8–9 hours and then the DNA precipitates were washed away and replaced with fresh medium with 10% charcoal-resin double stripped fetal bovine serum. 20-hydroxy-ecdysone (Sigma; 10 μg/ml in ethanol), or ethanol alone was then given to the cells. 24–28 hours later, the cells were harvested. Beta-galactosidase (βGal) activity was measured and a normalized amount of extract was used for CAT assay (Umesono et al. (1989) supra). The following amount of plasmid DNA was included in the 10 cm plate transfection: 250 ng each of CMX-EcR and RSVEcR; 500 ng of CMX-usp; 5 μg ΔMTV-EcRE-C; 5 μg of βGal internal control plasmid CH111 (a derivative of CH111, Promega). The amount of CMX plasmid was kept constant in each transfection by adding CMX-luciferase. PGEM4 was added to bring the total amount of plasmid DNA to 15 μg per plate.

Example V

Usp is the Drosophila Nuclear Factor that can Enhance RAR DNA Binding Activity

It has previously been shown that the DNA binding activity of bacterially expressed RAR can be enhanced by adding cell extracts to the binding reaction [Yang et al., Proceedings National Academy of Science USA 88:3559–3563 (1991)]. Extracts prepared from both mammalian cells and the Drosophila Schneider cell line 2 (S2) had similar effects [Yang et al., supra]. The presence of this enhancing activity in Drosophila cells indicates that a general conserved mechanism may be utilized in both mammals and Drosophila to regulate DNA binding activity of receptors like RAR. To address this question, experiments were set up to characterize this Drosophila nuclear activity in S2 cell extracts and in embryo extracts.

In gel mobility shift assays using a 32P-labelled natural RAR response element—βRAR [see SEQ ID NO:15, see also do The et al., in Nature Vol. 343:177–180 (1990); and Suvov et al., in Proceedings National Academy of Science USA Vol. 87:5392–5398 (1990)] as the probe, in vitro translated RARα was incubated with probe under binding conditions either alone or with 2 μg of S2 extracts or embryo extracts. In vitro translated RARα, by itself, did not bind with appreciable affinity. For mammalian extracts [Glass et al., Cell Vol. 63:729–738 (1990)], incubating the RARα with either S2 or Drosophila embryo extracts dramatically enhanced DNA binding activity, while cell extract alone did not show similar binding activity.

Two clues suggested the possibility that the observed enhancing activity might be the ultraspirectile receptor (usp). First, RXR, the putative vertebrate homologue of usp, has been shown to enhance RAR DNA binding [Yu et al., Cell Vol. 67:1251–1266 (1991); Kliever et al., Nature Vol. 355:446–449 (1992); Leid et al., Cell Vol. 68:377–395 (1992)]. Second, usp protein has been found to be present in both S2 and embryo extracts with relative abundance. Based on these observations, it was investigated whether usp is the Drosophila nuclear activity that can interact with RAR. An affinity purified antibody against usp, prepared as described in Example III, was added to the mobility shift reaction. The affinity purified antibody supershifted the majority of the protein DNA complex while preimmune serum had no effect in the mobility pattern. By incubating with higher concentration of usp antibody, essentially all the binding complex was supershifted. These results indicate that the activity present in both types of fly extracts can be attributed to usp protein and that usp is likely the major factor in the extract which interacts with RAR.

To further show that usp is indeed the Drosophila component involved in the RAR interactions, usp protein was in vitro translated in the rabbit reticulocyte lysate (see Example II for procedure employed) and tested whether in vitro translated usp can mimic the fly extracts’ activity to interact with RAR. Neither in vitro translated usp alone, nor RARα alone, bound to a βRAR probe. However, when the two proteins were incubated together, a prominent retarded complex appeared. This complex comigrated with the complex
detected in the RAR and cell extract mixing experiments. The presence of both usp and RAR protein in this protein/DNA complex was demonstrated by the antibodies raised against usp and RARs. Either the affinity purified usp antibody, or the RARs, specifically affected the protein/DNA complex, while preimmune sera had no effect. This complex likely represents an RAR/usp heterodimer, as it mobility is similar to the RXR/RAR complex which has been proposed to be a heterodimeric species [Yu et al., supra; Kliever et al., supra; Leid et al., supra]. Thus it is concluded that usp is the Drosophila nuclear activity which can interact with RAR in binding to specific RARE via the formation of a putative heterodimer.

Example VI

Usp can Heterodimerize with Several Members of the Mammalian Nuclear Receptor Family

The finding that usp is able to heterodimerize with RAR suggested that it would be appropriate to check whether this interaction reflected a general ability of usp to form heterodimers with other members of the steroid/thyroid superfamily. Using in vitro translated usp protein, interaction of usp with three mammalian nuclear receptors (TRβ, VDR and PPAR) was tested in gel mobility shift assays with the appropriate response element for each of the three receptors as the probes. Response elements used were as follows:

<table>
<thead>
<tr>
<th>Response Element</th>
<th>Abbreviation</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>AOX-PPARE</td>
<td>DR1</td>
<td>AGGACA A AGGATCA 25</td>
</tr>
<tr>
<td>SS1p-VDRE</td>
<td>DR3</td>
<td>GOTTCA CGA GGTCA  7</td>
</tr>
<tr>
<td>MLV-TRE</td>
<td>DR4</td>
<td>GOTTCA TTTG AGGATCA 12</td>
</tr>
<tr>
<td>PARE</td>
<td>DR5</td>
<td>GOTTCA CGGAA AGGATCA 15</td>
</tr>
</tbody>
</table>

1Kliever et al., submitted to Nature, entitled “9-Cis Retinoic Acid and Peroxisome Proliferator Signalling Pathways Converge Through RXR-PFAR Interactions”
2Noda et al., Proceedings National Academy of Science USA 87: 9985-9999 (1990)
3Sap et al., Nature 340:242-244 (1989)
4Sucov et al., supra.

For a review providing further discussion with respect to these response elements, see Umesono et al., 1991, supra. With any of the receptors alone (prepared by in vitro translation from cDNA clones) there was very little or no binding to the test probes. However, when they were incubated with usp, a dramatic increase in DNA binding activity could be detected. In a usp dependent fashion, TRβ binds to a natural TR response element (MLV-TRE) and VDR/usp bound to SS1p-VDRE, a natural VDR response element. The usp and PPAR interaction was tested on a PARE derived from the acyl CoA oxidase promoter (OX, Kliever et al., submitted, supra, and references cited therein). PPAR/usp complex bound to AOX-PPARE with high affinity. The usp antibody again showed the presence of usp in those complexes by shifting the retarded bands in all three combinations, whereas preimmune serum did not affect the binding pattern. Oligonucleotide competition assay demonstrated that the usp dependent heterodimers all showed correct response element specificity. Therefore, by interacting with usp to form heterodimer, all four mammalian receptors tested achieved high affinity DNA binding to their cognate response elements. It can be concluded, therefore, that the ability of usp to interact with other receptors to form heterodimers is a characteristic feature of usp, and that receptor heterodimer formation, as exemplified by RXR and usp, is conserved between vertebrates and invertebrates.

Example VII

Ecdysone Receptor and Usp can Heterodimerize to Form a High Affinity DNA Binding Complex

If the substitution of usp for RXR in heterodimerization with RAR and other mammalian receptors represents a conserved feature of mammalian and Drosophila receptors, it can be speculated that there might be one or more Drosophila activities which can interact with usp. The ligand binding domain has been shown to contain the dimerization domain for some nuclear receptors [Forman et al., Molecular Endocrinology Vol. 3:1610-1626 (1989); Fawell et al., Cell 60:953-962 (1990)] and it is also essential for interaction between RAR and nuclear factors including RXR [Glass et al., supra; Kliever et al. supra]. Sequence comparisons reveal that, with respect to the ligand binding domain, all RXR heterodimer partner receptors, RAR, TR and VDR, are much more similar to one another than to other receptors, particularly RXR. Among the Drosophila receptor members, ecdysone receptor (EcR) is one of the receptors which shows strong homology to RAR, VDR and TR within this region. This homology suggests EcR may have an evolutionarily conserved domain that, like RAR, VDR and TR, allows EcR to interact with usp.

To test the potential interaction between usp and EcR, experiments were carried out to determine whether usp is part of the defined EcR DNA binding activity present in ecdysone responsive Schneider 2 cells [Koele et al. Cell 67:59-77 (1991)]. As shown by Koele et al., in a gel mobility shift assay using a natural ecdysone response element derived from hsps27 promoter (32P-labelled hsps27-EcRE, Riddihough and Pelham, EMBO Journal Vol. 6:3729-3734 (1987)) as the probe, one specific major complex could be detected in the S2 extract. This complex can be competed away by specific cold oligonucleotide but not by the unrelated oligonucleotide competitor GREpal, a glucocorticoid response element. To determine whether usp is present in this EcRE binding complex, affinity purified usp antibody was added to the reaction. usp antibody can supershift the specific EcRE binding complex from the S2 extract but not the lower minor complex, which was much less sensitive to the specific cold oligonucleotide competition. Preimmune serum had no effect on the upper major complex but it disrupted the lower minor complex. Antibody against RXRα and RARα did not affect the specific complex. Therefore, these data demonstrate that usp is part of the EcRE DNA binding complex present in S2 cells, strongly suggesting an interaction between EcR and usp.

The EcR and usp interaction was also tested under more defined conditions. In vitro translated EcR and usp were prepared and their interaction was assayed by gel mobility shift assays. Using the same hsps27-EcRE as the probe, usp did not bind to this element by itself. EcR also failed to bind to hsps27-EcRE, in contrast to the EcRE binding activity in S2 cells. To test whether usp can complement EcR DNA binding, as it does with mammalian receptors, both usp and EcR were co-incubated in the reaction. In the presence of both receptors, a novel high affinity DNA binding complex appeared. Usp antibody, but not preimmune serum, can supershift the complex, demonstrating that usp is part of the complex. This complex is proposed to be a heterodimeric species, which is consistent with the observation of other usp heterodimers. These data demonstrate that EcR binding to ecdysone response element (hsps27-EcRE) depends upon usp.
and are consistent with the existence of a functionally significant EcR/usp complex.

Example VIII

DNA Binding Activity of EcR/usp Heterodimer is Correlated with the Ecdysone Responsiveness In Vivo

To establish that the EcR/usp heterodimer is physiologically relevant, it was set out to determine whether the DNA binding properties of EcR/usp heterodimer can be correlated with ecdysone responsiveness in vivo. This was done by testing EcR/usp heterodimer binding to several wild type and mutant EcREs characterized by their differential ability to mediate the ecdysone responsiveness in cultured cells (for review see Cherbas et al., *Genes & Development* Vol. 5:120–131 (1991)). The response elements used in this study are set forth below. The position and the orientation of ERE-like half sites (AGGTCA-like) are marked by arrows. For example, the palindromic motif in hsp27-EcRE is indicated by arrows arranged as →←. The mutated nucleotides in 11N and 15N-EcRE are in small letters. The arrow in 11N-EcRE covers where the remaining palindromic motif extends. In Eip28/29-EcRE, which is named as dis^*+Eip28/29 in Cherbas et al., supra, the half site which can constitute a highly degenerated palindromic is marked with a wavy, broken line. Note that two ERE half sites are present in the configuration of direct repeats spaced by three nucleotides in Eip28/29-EcRE. The ability of individual response elements to mediate ecdysone response in cultured cells (summarized from Cherbas et al., supra) and to serve as high affinity binding site for EcR/usp complex are summarized to the right of the sequences.

<table>
<thead>
<tr>
<th>Ability to Mediate Ecdysone Response</th>
<th>Ability to Function as Binding Site for ECR/usp Multimeric Complex</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsp27-EcRE ATTGGCAAGTGACATTGGACACCTTTGTCTC (SEQ ID NO 126) TAAAGGCAAGTGACATTGGACACCTTTGTCTC</td>
<td>+</td>
</tr>
<tr>
<td>11N-EcRE atgtgcaagtgacattggacactgctga (SEQ ID NO 27) tctgcaatcattgacactgctga</td>
<td>←→</td>
</tr>
<tr>
<td>15N-EcRE atgtgcaagtgacattggacactgctga (SEQ ID NO 128) tctgcaatcattgacactgctga</td>
<td>+</td>
</tr>
<tr>
<td>Eip28/29-EcRE TAAGGCAAGTGACATTGGACACCTTTGTCTC (SEQ ID NO 130) TAAAGGCAAGTGACATTGGACACCTTTGTCTC</td>
<td>←→</td>
</tr>
</tbody>
</table>

An EcRE derived from the Drosophila Eip28/29 gene has been shown to mediate ecdysone response in cultured cells [Cherbas et al., supra]. In contrast to the hsp27-EcRE palindrome, the Eip28/29-EcRE is a composite element containing a direct repeat and a highly degenerated palindromic motif. The ability of EcR/usp complex to recognize this EcRE was examined. This element can effectively compete the EcR/usp binding to hsp27-EcRE. This competition is as effective as that of the hsp27-EcRE itself, demonstrating that the Eip28/29-EcRE is also a high affinity binding site for EcR/usp complex. In contrast, an unrelated competitor (GREpaI) had no effect on the DNA binding. The high affinity binding by the EcR/usp complex parallels the ability the Eip28/29-EcRE to mediate ecdysone response in culture cells.

In contrast to the high affinity binding referred to above, a mutant hsp27-EcRE (referred as 11-N-hsp by Cherbas et al., supra, wherein the two nucleotides at the ends of the palindrome and the flanking sequence were changed), failed to serve as a high affinity binding site for the EcR/usp. This oligonucleotide did not compete the specific binding of EcR/usp to hsp27-EcRE, which was consistent with the observation that this mutated EcRE failed to confer ecdysone responsiveness to a heterologous promoter in transfection assay (Cherbas et al., supra). However, a back mutation which regenerated the palindrome motif (15-N-hsp) led to recovery of the ecdysone responsiveness and effective competition for the EcR/usp binding to the wild type hsp27-EcRE. Therefore, the ability of a specific EcRE motif to mediate the ecdysone response in vivo correlated well with its ability to serve as high affinity binding site for EcR/usp complex. These data suggest that the EcR/usp complex can mediate the ecdysone response in vivo.

Example IX

Usp Is Present in the Embryonic EcRE Binding Activity

Phenotypic analysis of usp reveals that it is required at a number of developmental events which are correlated with known or potential ecdysone-regulated processes. For
Based on the coexpression and functional requirement of both activities, it was next tested whether EcR and usp can interact during this developmental stage. To this end, the EcRE binding activities in the embryo extract were determined by mobility shift assay using 5–10 μg of embryo extract and 32P-labelled hsp27-EcRE as the probe. Specific EcRE binding complexes can be detected, as demonstrated by specific oligonucleotide and unrelated oligonucleotide competition. Indeed, usp is present in those complexes, as usp antibody was able to supershift those complexes. Pre-immune serum did not alter the mobility pattern, although a slightly enhanced overall DNA binding was observed. The detection of multiple EcRE binding complexes is consistent with the existence of multiple forms of EcR protein which have been reported (Koch et al., supra). The identities of these complexes as EcR complexes were supported by the fact that the upper complex comigrated with the EcR complex present in the S2 extract and that the DNA binding specificity of these complexes as assayed by oligonucleotide competition was indistinguishable from the EcR/usp complex prepared in vitro.

Based on these data, it can be concluded that the embryonic EcRE binding complexes contain usp. These data suggest an interaction between endogenous usp and EcR in the Drosophila embryo, where both activities are required for embryonic development.

**Example X**

Usp is Required for Ecdysone Responsiveness in Heterologous Cultured Cells

The in vitro DNA binding data suggests that usp is required for EcR high affinity DNA binding. The detection of EcR/usp heterodimeric DNA binding complex from embryo implies that they may interact in vivo. To determine whether usp and EcR can functionally interact in vivo, cotransfection experiments were set up to assay if usp is required for EcR to exert ecdysone response in cultured cells. Mammalian cells were chosen as the heterologous system because they do not contain endogenous EcR and usp background.

Ecdysone response in CV1 cells was determined by using an ecdysone-responsive reporter gene (ΔMTV-EcRE::CAT), which contains the same core hsp27-EcRE motif tested in DNA binding assay described earlier. The chloramphenicol acetyl transferase (CAT) activity induced by ecdysone was measured in the presence of different combinations of transfected EcR and usp expression vectors. CAT activity is expressed in FIG. 2 as the percentage of conversion which is normalized against the level in EcR alone at the presence of ecdysone assigned as one (column 1, shaded rectangle). The final concentration of 20-hydroxy-ecdysone (Sigma) is 40 μM. Columns 1 and 2 show that transfection with EcR alone (column 1) or usp alone (Column 2) does not respond to 20-OH-ecdysone treatment. Cotransfection of EcR and usp together is shown in column 3 and the induction of CAT activity could be observed by about 3 fold. The requirement of EcR for induction is demonstrated by using the parental ΔMTV-CAT as reporter. This construct does not respond to ecdysone (column 4).

As shown in FIG. 2A, transfection of EcR alone failed to confer responsiveness to 20-hydroxy-ecdysone, consistent with the idea that EcR by itself cannot mediate ecdysone response. To test whether usp can complement the EcR activity as did in the DNA binding assay, usp expression vector was cotransfected with EcR into CV1 cells. Cotransfection of usp with EcR indeed was able to confer a significant response to 20-OH-ecdysone (over 3 fold, FIG. 2A). This induction was strictly dependent on both EcR and EcRE, as transfection with usp expression plasmid alone or a reporter construct without EcRE (ΔMTV-CAT) did not result in ecdysone responsiveness (FIG. 2A). The level of induction by EcR and usp in CV1 cells is significant but somewhat lower than expected compared with the interaction in DNA binding assay.

To address the possibility that EcR may not function properly in mammalian cells, the N-terminal domain of the glucocorticoid receptor (GR) was fused to the EcR DNA binding domain and ligand binding domain to create the construct GECR (see Example 1). The presence of the GR N-terminal domain, which contains a transactivating domain [Hollenberg and Evans, supra], should increase the transcriptional potency and provide an optimal translation signal for Drosophila EcR protein to function properly in the mammalian cells. This construct retained the ability to interact with usp in DNA binding assay. Since usp did not interact with GR in either DNA binding or in transfection assay, it is clear that GR N-terminal fusion should not affect the basic property of EcR to interact with usp. A similar GR fusion protein with TR has been shown to behave like wild type TR except that it is a more potent transactivator [Thompson and Evans, Proceedings National Academy of Science USA Vol. 86:3494–3498 (1989)]. Therefore this system should increase the sensitivity of a functional interaction between usp and EcR while faithfully retaining the basic property of EcR.

As shown in FIG. 2B, expression plasmid of GECR was transfected into CV1 cells alone, or with usp expression plasmid. The conversion of CAT was normalized as described for panel A. Note that the scales of the CAT conversion in FIG. 2, panels A and B are different. Similar to the results obtained with wild type EcR, transfection of GECR alone failed to confer ecdysone response. However, when cotransfected with the usp expression plasmid, the 20-OH-ecdysone treatment induced CAT activity by 8–10 fold (FIG. 2B). This induction was also dependent on the presence of the EcRE in the reporter constructs. Thus, the GECR mediated ecdysone response is similar to EcR except the signal level is higher (compare FIGS. 2A and 2B). In conclusion, the presence of usp appears to be essential for EcR and GECR to exert an ecdysone response in CV1 cells. These data demonstrate that EcR and usp can interact in vivo and constitute a functional ecdysone response in a heterologous cell line.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.
SEQUENCE LISTING

(1) GENERAL INFORMATION:

(iii) NUMBER OF SEQUENCES: 29

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2304 base pairs
(B) TYPE: nucleic acid
(C) STRANDINESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 163..1701

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
GAC CAG GAC GCC AGC TTT CGG CTG AGC CAC ATC AAG GAG GAG GTC AAG

Aep Gln Asp Ala Ser Phe Arg Leu Ser His Ile Lys Glu Glu Val Lys

GCG GAC ATC TCG CAG CTG AAC GAC AGC AAC ACC ACC TTT TCG CCC

Pro Asp Ile Ser Gin Leu Asp Asn Ser Asn Ser Phe Ser Pro

AAG GCC GAG AGT CCC GTU CCC TTC ATG CAG GCC ATG TCC ATG GTC CAC

Lys Ala Glu Ser Pro Val Pro Phe Met Gin Ala Met Ser Met Val His

GTT CTG CCC GCC TCC AAC TCC GCC ACC TCC AAC ACC AAC ACC GCT GGA

Val Leu Pro Gly Ser Asn Ser Ala Ser Asn Asn Ser Ala Gly

GAT GCC CAA ATG GCC CCC ATG GCC CCC GAT GCT GAA GCC TCT GCC GCC

Asp Ala Gin Met Ala Gin Leu Asn Ala Gly Gly Ser Ala Ala

GCT GCA GTC CAG CAG CAA TAT CCC CCT AAC CAT CCT GCG AGG GCC ACC

Ala Ala Val Gin Gin Tyr Pro Pro Asn His Pro Leu Ser Gly Ser

AAG CAC CTC TGC TCT ATT TGC CGG GAT CGG GCC AUG GCU CAC TAC

Lys His Leu Cys Ser Ile Cys Gly Asp Ala Ser Ala Ser Lys His Tyr

GUC GTG TAC AGC TGT GAG GCC TGC AAC GCC TTT TGA TAT AAA CCC ACA GTG

Gly Val Tyr Ser Cys Gly Glu Cys Lys Gly Phe Phe Lys Arg Thr Val

GCC GAC GAT CTG ACA TAC GCT TGC AGG GAG AAC CCC AAC TGC ATC ATA

Arg Lys Asp Leu Thr Tyr Ala Cys Arg Gly Asn Cys Ile Ile

GAC AAG CGG CAG AGG AAC GCC AGC TGC CAG TAC TGC GCC TAC GAG TGC

Asp Lys Arg Gin Arg Asn Arg Cys Gin Tyr Cys Arg Tyr Gin Lys Cys

CTA ACC TGC GCC ATG AAG GCC GAA GCG GTC CAG GAG GCT CAA GCC

Leu Thr Cys Gly Met Lys Arg Glu Ala Val Gin Glu Glu Arg Gin Arg

GTC GCC CGC TAT GCG GCG GCT GAT AGG CTC AGC GCC GAC GAA GCC GGC GCT

Gly Ala Arg Asn Ala Ala Gly Arg Leu Ser Ala Ala Gly Gly Ser

```

23 24
<table>
<thead>
<tr>
<th></th>
<th>505</th>
<th>510</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CCCCCCCTGCC ATCCGAAAAA TGTTTCATG TGATTCGTT TGTGGCAAT TCCCTCCT</td>
<td>1771</td>
</tr>
<tr>
<td></td>
<td>ATCCTCAACA AACCGCCCTA ATAGATACA AAAATCTAT GTATTTTTT ATTTTTTTT</td>
<td>1831</td>
</tr>
<tr>
<td></td>
<td>TATTTACAAA TCTTATTTAT TATTTAGAA TAGAATTTT TCAGAAAGA AATGACAT</td>
<td>1891</td>
</tr>
<tr>
<td></td>
<td>GCCTGCTGCA ATTTTATGAC CCAATACGA AAAACAAAC AAAATCCAA ACAATGAAAAG</td>
<td>1951</td>
</tr>
<tr>
<td></td>
<td>AACACCAAC ACAGCAAGA AAATCACAAC AAGCAAGTAG AAGGTAAGAA TTAACTAAA</td>
<td>2011</td>
</tr>
<tr>
<td></td>
<td>GCTAAACGAG TAAAGATATT AAAATAACCG TTAAATTAA TGCTATGTTA TGATCTACAG</td>
<td>2071</td>
</tr>
<tr>
<td></td>
<td>ACATATAGAA ATATCGAGAA TCAAGTGATA TTTTAGAGA GAGGCGCA ATATCTGCGT</td>
<td>2131</td>
</tr>
<tr>
<td></td>
<td>GCTGCCCGCG TGCTAAACCA ATTUTAAATCTTTTAAACA TAAAATTTACC CAAAACUTTT</td>
<td>2191</td>
</tr>
<tr>
<td></td>
<td>TCAAATGAT GCAGATACGA AAAATCAGCC ACAAAACAC ACAATATATA TCTATATATA</td>
<td>2251</td>
</tr>
<tr>
<td></td>
<td>AAAATATATA GCTGATAAC AAAAAAAAAA AAAAAAAA AAA AAAA</td>
<td>2394</td>
</tr>
</tbody>
</table>

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 513 amino acids
   (B) TYPE: amino acid
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(x) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Asp Asn Cys Asp Glu Asp Ser Phe Arg Leu Ser His Ile Lys
1  5  10  15
Glu Glu Val Lys Pro Asp Ile Ser Glu Leu Asn Asp Ser Asn Ser
20  25  30
Ser Phe Ser Pro Lys Ala Glu Ser Pro Val Pro Phe Met Glu Ala Met
35  40  45
Ser Met Val His Val Leu Pro Gly Ser Asn Ser Ala Ser Ser Asn
50  55  60
Asn Ser Ala Gly Asp Ala Glu Met Ala Glu Pro Asn Ser Ala Gly
65  70  75  80
Gly Ser Ala Ala Ala Val Gln Glu Tyr Pro Pro Asn His Pro
85  90  95
Leu Ser Gly Ser Lys His Leu Cys Ser Ile Cys Gly Asp Arg Ala Ser
100 105 110
Gly Lys His Tyr Gly Val Tyr Ser Cys Glu Gly Cys Lys Gly Phe Phe
115 120 125
Lys Arg Thr Val Arg Lys Asp Leu Thr Tyr Ala Cys Arg Glu Asn Arg
130 135 140
Asn Cys Ile Ile Asp Lys Arg Glu Asp Asn Asp Cys Cys Gln Tyr Cys Arg
145 150 155 160
Tyr Glu Lys Cys Leu Thr Cys Gly Met Lys Arg Glu Ala Val Glu Glu
165 170 175
Glu Arg Glu Arg Gly Ala Arg Ala Gly Arg Leu Ser Ala Ser
180 185 190
Gly Gly Ser Ser Gly Pro Gly Ser Val Gly Gly Ser Ser Glu
195 200 205
215 220 225
Gly Ser Asp Asp Phe Met Thr Asn Ser Val Ser Arg Asp Phe Ser Ile
225 230 235 240
Glu Arg Ile Ile Glu Ala Glu Gln Arg Ala Glu Thr Gln Cys Gly Asp
245 250 255
Arg Ala Leu Thr Phe Leu Arg Val Gly Pro Tyr Ser Thr Val Gln Pro
260 265 270
Asp Tyr Lys Gly Ala Val Ser Ala Leu Cys Gln Val Val Asn Lys Gln
275 280 285
Leu Phe Gln Met Val Glu Tyr Ala Arg Met Met Pro His Phe Ala Gln
290 295 300
Val Pro Leu Asp Asp Gln Val Ile Leu Leu Lys Ala Ala Trp Ile Glu
305 310 315 320
Leu Leu Ile Ala Asn Val Ala Ala Cys Ser Ile Val Ser Leu Asp Asp
325 330 335
Gly Gly Ala Gly Gly Gly Gly Gly Gly Leu Gly His Asp Gly Ser Phe
340 345 350
Glu Arg Arg Ser Pro Gly Leu Gln Pro Gln Gln Leu Phe Leu Asn Gln
355 360 365
Ser Phe Ser Tyr His Arg Asn Ser Ala Ile Lys Ala Gly Val Ser Ala
370 375 380
Ile Phe Asp Arg Ile Leu Ser Glu Leu Ser Val Lys Met Lys Arg Leu
385 390 395 400
Aaa Leu Asp Arg Arg Glu Leu Ser Cys Leu Lys Ala Ile Ile Leu Tyr
405 410 415
Aaa Pro Asp Ile Arg Gly Ile Lys Ser Arg Ala Glu Ile Gly Met Cys
420 425 430
Arg Glu Lys Val Tyr Ala Cys Leu Asp Glu His Cys Arg Leu Glu His
435 440 445
Pro Gly Asp Asp Gly Arg Phe Ala Gln Leu Leu Arg Leu Arg Arg
450 455 460
Phe Ala Ile Asp Gln Pro Glu Val Pro Gly Ser Pro Val Pro Leu Pro
465 470 475 480
His Tyr Gln Arg Pro Ala Ala Gly Ala Leu Ser Arg Ala Ala Gly
485 490 495
Gly Ala Ala Ala Thr Arg Pro Gly Asp Glu Thr Gly Val Gly Ser Arg
500 505 510
Leu

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 71 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Cys Xaa Xaa Cys Xaa Xaa Asp Xaa Ala Xaa Gly Xaa Tyr Xaa Xaa Xaa
1  5  10  15
Xaa Cys Xaa Xaa Cys Xaa Phe Phe Xaa Arg Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
35 40 45
Xaa Xaa Xaa Lys Xaa Xaa Arg Xaa Xaa Cys Xaa Xaa Cys Arg Xaa Xaa
50 55 60
Lys Cys Xaa Xaa Xaa Gly Met
(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
AGCTCAAGGA GCTCA

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
GGCTGAATGA GGACA

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
GGCTGAACGG GGACA

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
GGTTCAGGG GTTCA

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
AGCTCAAGGG AGTCA

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
AGCTGACAGG AGTCA
(2) INFORMATION FOR SEQ ID NO:10:
   (i) SEQUENCE CHARACTERISTICS:
       (A) LENGTH: 16 base pairs
       (B) TYPE: nucleic acid
       (C) STRANDEDNESS: single
       (D) TOPOLOGY: linear
   (ix) SEQUENCE DESCRIPTION: SEQ ID NO:10:

AGUTGACGG AGGACA

(2) INFORMATION FOR SEQ ID NO:11:
   (i) SEQUENCE CHARACTERISTICS:
       (A) LENGTH: 16 base pairs
       (B) TYPE: nucleic acid
       (C) STRANDEDNESS: single
       (D) TOPOLOGY: linear
   (ix) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGUTTADGG AGGACA

(2) INFORMATION FOR SEQ ID NO:12:
   (i) SEQUENCE CHARACTERISTICS:
       (A) LENGTH: 16 base pairs
       (B) TYPE: nucleic acid
       (C) STRANDEDNESS: single
       (D) TOPOLOGY: linear
   (ix) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GGUTCAATTC AGGTOC

(2) INFORMATION FOR SEQ ID NO:13:
   (i) SEQUENCE CHARACTERISTICS:
       (A) LENGTH: 17 base pairs
       (B) TYPE: nucleic acid
       (C) STRANDEDNESS: single
       (D) TOPOLOGY: linear
   (ix) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AGUTCACCAG GAGOTCA

(2) INFORMATION FOR SEQ ID NO:14:
   (i) SEQUENCE CHARACTERISTICS:
       (A) LENGTH: 17 base pairs
       (B) TYPE: nucleic acid
       (C) STRANDEDNESS: single
       (D) TOPOLOGY: linear
   (ix) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AGUTCAACAG GAGOTCA

(2) INFORMATION FOR SEQ ID NO:15:
   (i) SEQUENCE CHARACTERISTICS:
       (A) LENGTH: 17 base pairs
       (B) TYPE: nucleic acid
       (C) STRANDEDNESS: single
       (D) TOPOLOGY: linear
   (ix) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GGUTTACGGA AAGTCCA
(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GTTCACCCA AAGTCTCA

17

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

AGUTCACC A CAGGSCA

17

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GGUTCATCA GAGTTCA

17

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

AAGCTTAAG GTTACCAGA AGTTCACCCA GCTT

34

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

AAGCTTAAG GTTACCAGA AGTTCACCG CATAGCCT

38

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AAGCTTAAG GTTACCAGA AGTTCACCG CATATAATTAG CTT

43
(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:22:
AGCTGATGACAAAGCAGTGGAACCGCCTTGAGCTACCTUTCAGGTTAAGCGTTGTC
50
GA
62

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:23:
CCTGCGCACCAGGCGGCCCCGCGACTCTGCTG
33

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:24:
GGGGTGATGCGCGAATGCTGCAGTGGCC
29

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:25:
AGGACAAGG TCA
13

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:26:
ATTGGACAGTGCCATTGGAACCCCTTCTCTCT
30

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:27:
ATGCTGAGCTGAACGTGCGCAAG
24
That which is claimed is:

1. An isolated multimeric receptor, wherein at least one subunit of said multimeric receptor is an ultraspiracle receptor, and wherein at least one subunit of said multimeric receptor is a hormone binding protein, wherein said hormone binding protein is characterized by having a DNA-binding domain having the amino acid sequence set forth in SEQ ID NO: 3.

2. A multimeric receptor according to claim 1 wherein said multimeric receptor is a heterodimer.

3. A multimeric receptor according to claim 1 wherein said multimeric receptor is a heterotrimer.

4. A multimeric receptor according to claim 1 wherein said multimeric receptor is a heterotetramer.

5. A multimeric receptor according to claim 1 wherein said hormone binding protein is an insect derived member of the steroid/thyroid superfamily of receptors.

6. A multimeric receptor according to claim 1 wherein said hormone binding protein is PPAR, VDR, TRα, TRβ, RARα, RARβ or RARγ.

7. A multimeric receptor according to claim 1 wherein said hormone binding protein is PPAR, VDR, TRα, TRβ, RARα, RARβ or RARγ.

8. An isolated multimeric receptor comprising a first subunit and a second subunit, wherein said first subunit is an ultraspiracle receptor and wherein said second subunit is a non-insect member of the steroid/thyroid hormone superfamily of receptors.

9. An isolated receptor according to claim 8 wherein said second subunit is peroxisome proliferator-activated receptor (PPAR).

10. An isolated receptor according to claim 8 wherein said second subunit is vitamin D receptor (VDR).

11. An isolated receptor according to claim 8 wherein said second subunit is thyroid hormone receptor (TR).

12. An isolated receptor according to claim 8 wherein said second subunit is retinoic acid receptor (RAR).

13. An isolated receptor according to claim 11 wherein said thyroid hormone receptor is thyroid hormone receptor alpha (TRα).

14. An isolated receptor according to claim 11 wherein said thyroid hormone receptor is thyroid hormone receptor beta (TRβ).

15. An isolated receptor according to claim 12 wherein said retinoic acid receptor is retinoic acid receptor alpha (RARα).

16. An isolated receptor according to claim 12 wherein said retinoic acid receptor is retinoic acid receptor beta (RARβ).

17. An isolated receptor according to claim 12 wherein said retinoic acid receptor is retinoic acid receptor gamma (RARγ).